Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04447768 · ClinicalTrials.gov registry record · Phase 2
The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)
A Phase 2 study of Chronic Lymphocytic Leukemia (CLL), sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 8
- Study locations
NCT04447768 is a Phase 2 study of Chronic Lymphocytic Leukemia (CLL) that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 100 participants, below the 188-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (47% lower). The trial reports 8 study locations across 4 states.
The verdict
NCT04447768, a Phase 2 study of Chronic Lymphocytic Leukemia (CLL), is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study will help researchers collect more information about how effective the combination of venetoclax and obinutuzumab is in treating CLL in people who have not received a previous treatment for their cancer.
Conditions Studied
Interventions
- DRUG Obinutuzumab
- DRUG Venetoclax
Study Locations (8)
New York
- Memorial Sloan Kettering Commack (All protocol activities) - Commack
- Memorial Sloan Kettering Westchester (All protocol activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (All protocol activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (All protocol activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (All protocol activities) - Middletown
California
- Stanford University Medical Center (Data collection only) - Stanford
North Carolina
- University of North Carolina - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2020-12-03 |
| Est. Completion | 2026-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04447768
The ClinicalTrials.gov registry entry for NCT04447768 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 188-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (47% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Lymphocytic Leukemia (CLL) appearing as the primary indexed condition, and to 2 interventions - of which Obinutuzumab is the first listed.
NCT04447768 reports 8 study locations spanning 4 distinct geographic areas - top geographies include New York, New Jersey, California.
Frequently Asked Questions
What is clinical trial NCT04447768 about?
NCT04447768 is a clinical study titled "The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)". This study will help researchers collect more information about how effective the combination of venetoclax and obinutuzumab is in treating CLL in people who have not received a previous treatment for their cancer.
What is the current status of trial NCT04447768?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2020-12-03. Estimated completion is 2026-07.
What conditions does trial NCT04447768 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia (CLL).
What interventions are being tested in trial NCT04447768?
The interventions under investigation include: Obinutuzumab (DRUG), Venetoclax (DRUG).
Who is sponsoring clinical trial NCT04447768?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04447768 being conducted?
This trial has 8 study locations across California, New Jersey, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia (CLL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
RECRUITING · Phase 2
-
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
RECRUITING · Phase 2
-
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
RECRUITING · Phase 2
-
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 2
-
Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax
ACTIVE NOT RECRUITING · Phase 2
-
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.